Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Proteotoxic Stress and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VCP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VCP Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View VCP Products |
| Gene Delivery | VCP Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View VCP Products |
| Benchmark Ab | Anti-VCP Antibody Recombinant positive control. |
View VCP Products |
| Validator | VCP siRNA Set For knockdown verification. |
View VCP Products |
| Related Target A | NPLOC4 Essential co-factor forming the VCP-NPL4-UFD1 complex, critical for ubiquitin-dependent protein degradation. |
View NPLOC4 Products |
| Related Target B | PSMB5 Proteasome subunit; crucial for evaluating synergistic proteasome-VCP inhibition. |
View PSMB5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-throughput ATPase screening | Recombinant VCP WT protein with verified high purity (>95%) and sequence accuracy |
| Target-specific toxicity assessment | Recombinant disease-associated mutants (e.g., R155H, A232E) for specificity profiling |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live VCP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VCP therapeutics is intensifying, with major players shifting focus from traditional competitive inhibitors to highly selective allosteric inhibitors and PROTACs (Proteolysis Targeting Chimeras). As first-generation therapies reach the clinic, the next wave of R&D is targeting drug-resistant mutations and multi-protein complexes associated with proteotoxic stress.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Cleave Therapeutics, Cleave Biosciences | AML, Solid Tumors | ATPase Activity Assay (Need high-purity recombinant WT VCP) |
| PROTAC (VCP Degrader) | Arvinas, Kymera Therapeutics | Oncology, Neurodegeneration | Protein Degradation Assay (Need high-quality VCP antibodies & siRNA) |
| Small Molecule (Orthosteric) | Academic/Biotech Consortia | Triple-Negative Breast Cancer | Selectivity Assay (Need Mutant vs WT VCP Proteins) |